|
Drugs | Authors | Animal or cell type | Animal or cell model | Administration dose and way | Effect |
|
2% hydrogen |
Liu et al. (2013) [42] | Wister rats | 15 mg/kg LPS (septic shock) | Inhalation for 2 h after LPS injection | Anti-inflammatory (IL-6, IL-8, TNF-, and MPO) Antioxidant (·OH, MDA, and SOD) Inhibition of apoptosis (Fas, Bcl-2) |
|
Hydrogen-rich saline | Chen et al. (2013) [43] | RAW 264.7 macrophages | 1 mg/mL LPS | Incubation with hydrogen-rich saline | Anti-inflammatory (TNF-, IL-1β, HMGB1, and IL-10) Nrf2/HO-1 signaling pathway |
|
Hydrogen-rich saline |
Xie (2013) [44] | Wister rats | CLP | 5 mL/Kg or 10 mL/Kg | Anti-inflammatory (MPO) Antioxidant (iNOS) |
|
2% H2 and 98% hyperoxia | Xie et al. (2012) [41] | C57BL/6 mice | CLP | 2% H2 and 98% hyperoxia for 3 h and 6 h after CLP | Anti-inflammatory (TNF-, HMGB1, IL-10, and MPO) Antioxidant (CAT, SOD, and 8-iso-PGF2) |
|
Hydrogen-rich saline | Li et al. (2013) [45] | Sprague-Dawley rats | CLP | 5 mL/Kg hydrogen-rich saline at 0, 6, and 18 h after CLP | Anti-inflammatory (TNF-, IL-6, HMGB1, IL-10, HMGB1, and MPO) Antioxidant (MDA, SOD) |
|
2% hydrogen | Xie et al. (2012) [46] | C57BL/6 mice | CLP | 2% H2 inhalation for 1 h and 6 h after CLP | Nrf2/HO-1 signaling pathway |
|
2% hydrogen or hydrogen-rich saline | Xie et al. (2012) [29] | C57BL/6 mice | 25 ug LPS (acute lung injury) | 2% H2 inhalation for 1 h and 6 h after LPS given or 10 mL/Kg hydrogen-rich saline | Anti-inflammatory (TNF-, IL-1β, IL-6, IL-10, KC, MIP-1, MIP-2/MCP-1, and MPO) NF-κB signaling pathway Inhibition of apoptosis (TUNEL, caspase-3) |
|
2% hydrogen | Xie et al. (2010) [30, 47] | C57BL/6 mice | CLP | 2% H2 inhalation for 1 h and 6 h after CLP | Anti-inflammatory (HMGB1, MPO) Antioxidant (CAT, SOD, and 8-iso-PGF2) |
|
2% hydrogen | Xie et al. (2010) [16] | ICR mice | 1 g/Kg zymosan (inflammation model) | 2% H2 inhalation for 1 h and 6 h after zymosan injection | Anti-inflammatory (TNF-α, HMGB1) Antioxidant (SOD, 8-iso-PGF2) |
|